|
|
|
|
|
Epirubicin
drug data and news
Epirubicin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Epirubicin | ||
| Brand Names/Synonyms | 4'-Epiadriamycin; 4'-Epidoxorubicin; CCRIS 2261; Ellence; Epi-Dx; Epiadriamycin; Epidoxorubicin; Epirubicin; Epirubicina [Inn-Spanish]; Epirubicina [Spanish]; Epirubicine [French]; Epirubicine [Inn-French]; Epirubicinum [Inn-Latin]; Epirubicinum [Latin]; HSDB 6962; IMI 28; Pharmorubicin Pfs; Pidorubicina [Inn-Spanish]; Pidorubicine [Inn-French]; Pidorubicinum [Inn-Latin]; Ridorubicin; WP 697 | ||
| Indication | For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Epirubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Epirubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Epirubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific. | ||
| Mechanism Of Action | Epirubicin has antimitotic and cytotoxic activity. It inhibits nucleic acid (DNA and RNA) and protein synthesis through a number of proposed mechanisms of action: Epirubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. It also interferes with DNA replication and transcription by inhibiting DNA helicase activity. | ||
| Epirubicin News (When available) |
Adjuvant Taxotere® and Herceptin® Effective for Breast Cancer ... 06 Mar 2006 Addition of Ellence® to Standard Chemotherapy Does Not Improve ... Mar 2, 2006 YM's Breast-Cancer Drug is Fast-Tracked Feb 13, 2006 Intensive Therapy May Benefit Women With Breast Cancer of a Poor ... Feb 14, 2006 Optimising Herceptin-based Therapy in HER2-positive Metastatic ... Feb 22, 2006 YM BioSciences Receives FDA Fast Track Designation for Tesmilifene ... Feb 13, 2006 Adjuvant Docetaxel More Effective Than Vinorelbine for Early ... Feb 23, 2006 What Can Xeloda (capecitabine) Add to Neoadjuvant Chemotherapy? ... Feb 22, 2006 Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for ... Feb 22, 2006 Recurrence-Free Survival Improved with Taxotere® Compared to ... Feb 23, 2006 Lamivudine Curbs Hepatitis B Virus Reactivation in Liver Cancer Feb 9, 2006 | ||
| Dosage Forms | POWDER FOR SOLUTION; SOLUTION | ||
| Drug_Category | Antineoplastic Agents; ATC:L01DB03 | ||
| Absorption | 100% | ||
| Interactions |
-->Interactions for Epirubicin: ELLENCE when used in combination with other cytotoxic drugs may show on-treatment additive toxicity, especially hematologic and gastrointestinal effects. Concomitant use of ELLENCE with other cardioactive compounds that could cause heart failure (e.g., calcium channel blockers), requires close monitoring of cardiac function throughout treatment. There are few data regarding the coadministration of radiation therapy and epirubicin. In adjuvant trials of epirubicin-containing CEF-120 or FEC-100 chemotherapies, breast irradiation was delayed until after chemotherapy was completed. This practice resulted in no apparent increase in local breast cancer recurrence relative to published accounts in the literature. A small number of patients received epirubicin-based chemotherapy concomitantly with radiation therapy but had chemotherapy interrupted in order to avoid potential overlapping toxicities. It is likely that use of epirubicin with radiotherapy may sensitize tissues to the cytotoxic actions of irradiation. Administration of ELLENCE after previous radiation therapy may induce an inflammatory recall reaction at the site of the irradiation. Epirubicin is extensively metabolized by the liver. Changes in hepatic function induced by concomitant therapies may affect epirubicin metabolism, pharmacokinetics, therapeutic efficacy, and/or toxicity. Cimetidine increased the AUC of epirubicin by 50%. Cimetidine treatment should be stopped during treatment with ELLENCE. Drug-Laboratory Test Interactions There are no known interactions between ELLENCE and laboratory tests. | ||
| Toxicity | bone marrow aplasia, grade 4 mucositis, and gastrointestinal bleeding | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 10-(4-amino-5-hydroxy-6-methyl-oxan-2-yl)oxy-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione | ||
| Chemical Formula | C27H29NO11 | ||
| Molecular Weight | 543.519 g/mol | ||
| Smiles String | CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)O | ||
| Melting Point | 344.53°C | ||
| Water Solubility | 0.093 mg/ml | ||
| State | Solid | ||
| LogP/Hphobicity | 0.455 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | half-lives for the alpha, beta, and gamma phases of about 3 minutes, 2.5 hours and 33 hours, respectively | ||
| Protein Binding [%] | 77% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Epirubicin.html http://www.rxlist.com/cgi/generic2/epirub.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00361 | ||
| CAS Registry Number | 56420-45-2 | ||
| KEGG Compound ID | C11230 | ||
| PubChem ID | SID:182518 | ||
| PharmGKB ID | PA449476 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2069512 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |